Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
Taro Kishi,1 Yuki Matsuda,1 Shinji Matsunaga,1 Masatsugu Moriwaki,1,2 Yoichiro Otake,2 Kaku Akamatsu,3 Tomo Okochi,4 Shigeki Hirano,4 Toshihiko Funahashi,5 Momoko Okuda,6 Hideaki Tabuse,6 Kiyoshi Fujita,2 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, 2Departmen...
Guardado en:
Autores principales: | Kishi T, Matsuda Y, Matsunaga S, Moriwaki M, Otake Y, Akamatsu K, Okochi T, Hirano S, Funahashi T, Okuda M, Tabuse H, Fujita K, Iwata N |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e08792372efe44ce84e76d859348dd3c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro/In Vivo Evaluation
por: Soraia Silva, et al.
Publicado: (2021) -
Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study
por: Otsubo T, et al.
Publicado: (2018) -
Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety
por: Wang G, et al.
Publicado: (2018) -
Mind your state: Insights into antidepressant nonadherence
por: De Wet Wolmarans, et al.
Publicado: (2016) -
Dosage-related nature of escitalopram treatment-emergent mania/hypomania: a case series
por: Yamaguchi Y, et al.
Publicado: (2018)